Although a greater sphere formation ability of CD166+ cancer cells has been reported in colon cancer, prostate cancer, and head and neck squamous cell carcinoma [6], [7], [30], our study showed that there was no significant difference in the sphere formation capacities of CD166+ and CD166- cells. Here, ALCAM is linked to prostate carcinoma.